Navigation Links
Media Statement on Nuclear Crisis in Japan: Fleming Pharmaceuticals Stepping Up Production of Nuclear Antidote
Date:3/15/2011

ST. LOUIS, March 15, 2011 /PRNewswire/ -- Fleming Pharmaceuticals, maker of ThyroShield – one of two FDA-approved potassium iodide medicines used in nuclear emergencies to block the thyroid gland from absorbing radioactive iodine to avoid thyroid cancer – is stepping up production of ThyroShield to help provide domestic and global relief.  

ThyroShield is an iodide solution which, when taken orally, saturates the thyroid gland so radioactive iodine cannot be absorbed. The Fleming form of potassium iodide is especially effective for babies and children, given the easy dosing liquid formula.

"ThyroShield is not routinely stocked in large quantities but we are putting a plan in place that expedites production and delivery," states Phill Dritsas, president of Fleming Pharmaceuticals. "However, in the case of Japan, we simply don't have enough inventory to even begin to fill a need that great and immediate."

Under a 2002 federal law, states and local governments are required to provide potassium iodide medicine for citizens living within 20 miles of any of the 104 U.S. nuclear power plants. To that end, the federal government has stockpiled millions of doses of potassium iodide in liquid and pill form for states and local governments to distribute.

"Some of the nation's stockpile of ThyroShield has already expired and the remaining inventory will expire over the next year and a half. If federal officials were to decide to donate the existing medicine, while it is still viable, for humanitarian efforts in Japan, that could address the immediate need there AND give us time to accelerate production here and work with the federal government to replenish what was donated," Dritsas says.  

"The scope of the issue goes beyond Japan however," Dritsas explains. "Some Americans on the West Coast are fearful that the radiation from Japan could drift to our shores, although that is not a real threat according to authorities.  And of course there is always the possibility of an unrelated leak here on our own soil. The Japan incident has heightened awareness of the dangers of radiation exposure."

For more information, visit www.flemingpharma.com.


'/>"/>
SOURCE Fleming Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Hospital to Hold MRSA Briefing for Media and Community Leaders
3. Superbug Outbreak Calls for Immediate Increased Attention on Infection Control
4. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
5. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
6. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
9. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017 Research and Markets ... - Forecast to 2021" report to their offering. ... The interventional radiology products ... USD 6.35 Billion in 2016, at a CAGR of 4.8%. This ... The major factors driving the growth of this market are ...
(Date:1/23/2017)... , Jan. 23, 2017  Delcath Systems, Inc. ... focused on the treatment of primary and metastatic liver ... Ph.D., MSN, CRNP, President and Chief Executive Officer of ... - Noble Capital Markets, Thirteenth Annual Investor Conference at ... Boca Raton, Florida , on Tuesday, January 31, ...
(Date:1/23/2017)... , January 23, 2017 ... (r enal) y el riesgo ... de a pabetalone    Resverlogix Corp. ... resultados preliminares de un ensayo en fase 1 con ... de riñón (renal) severa. Los datos demostraron unos resultados ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... ... statement on the imposition of the Mexico City Policy, also known as the ... again today through Executive action, prohibits foreign non-governmental organizations from receiving any U.S. ...
(Date:1/24/2017)... ... January 23, 2017 , ... Somnoware, a leading ... allows sleep centers to automatically connect and initialize all their devices with one ... plugin is quickly installed on first use and then monitors device changes automatically. ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... nonprofit educational institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 ... present by Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. ...
(Date:1/23/2017)... ... 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and feared ... benefits of making new water infrastructure a number one priority. “As we usher in ... water infrastructure to become a top priority of our new political change agents.” Kleyne ...
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, ... certification under the USDA National Organic Program (NOP) for its Portland SQF Level ... established organic production and handling systems to complement our current rigorous food-safety management ...
Breaking Medicine News(10 mins):